Active Ingredient(s): Omadacycline Tosylate
FDA Approved: * October 2, 2018
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nuzyra Overview

Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass[2] of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections. Contents 1 In vitro studies 2 Mechanism of action 3 Clinical trials 4 Discovery 5 References 6 External links In vitro studies In vitro studies h...

Read more Nuzyra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nuzyra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Omadacycline Tosylate
  • Powder: 100mg/vial
  • Tablet: 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nuzyra: (2 results)

Sorted by National Drug Code
  • 71715-001 Nuzyra 100 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Paratek Pharmaceuticals, Inc.
  • 71715-002 Nuzyra 150 mg Oral Tablet, Film Coated by Paratek Pharmaceuticals, Inc.

Other drugs which contain Omadacycline Tosylate or a similar ingredient: (1 result)